Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.83 per common share, reflecting a 5.1% increase from the previous quarter. This dividend will be payable on December 31, 2020 to shareholders recorded by December 10, 2020. The annual dividend rate for fiscal year 2021 is $3.32 per share. This marks the 49th consecutive year of dividend increases, underscoring BD's confidence in its long-term outlook despite challenges posed by COVID-19.
BD (Becton, Dickinson and Company) announced new reporting capabilities for COVID-19 data through the BD Synapsys™ Informatics solution (version 3.84). This enhances reporting for users of the BD Veritor™ Plus and BD MAX™ systems, both FDA authorized for SARS-CoV-2 testing. The system allows users to generate daily reports compliant with the U.S. CARES Act, streamlining mandatory reporting to health authorities. The updated capabilities aim to reduce manual reporting burdens, ultimately facilitating timely public health responses.
BD (Becton, Dickinson and Company) (NYSE: BDX) will present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 2, 2020, at 8:00 a.m. ET. A live webcast will be available on the BD corporate website, with a replay accessible for seven days post-event. BD is a global leader in medical technology, dedicated to advancing health through innovative solutions. With a workforce of 65,000, the company aims to improve clinical therapy, diagnostic accuracy, and healthcare efficiency worldwide. For further details, visit www.bd.com/investors.
BD (Becton, Dickinson and Company) has acquired the Medical Business assets of CUBEX LLC, enhancing its medication management solutions. This acquisition integrates CUBEX's MedBank cloud-based software with BD's Pyxis™ Automated Dispensing Cabinets. The move aims to improve patient care across various healthcare settings, addressing challenges like medication diversion and inventory management. Approximately 40 CUBEX employees will join BD. Terms of the deal were not disclosed, but it will not affect BD's fiscal 2021 guidance.
BD (Becton, Dickinson and Company) has received authorization from Health Canada for its rapid SARS-CoV-2 antigen test, part of a government order for 7.6 million tests to enhance COVID-19 testing capabilities. The test provides results in about 15 minutes, enabling quicker decision-making at the point-of-care. Designed to ease the load on labs, this mid-nasal swab test is less invasive than traditional methods. The BD Veritor™ Plus System, already in use for other diagnostics, will support public health efforts across Canada.
BD (Becton, Dickinson and Company) (NYSE: BDX), a key player in global medical technology, announced its participation in two upcoming virtual healthcare conferences. The Stifel 2020 Virtual Healthcare Conference is scheduled for November 16, 2020, at 9:20 a.m. EDT, followed by the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 7:55 a.m. EDT. Investors can access live webcasts on the corporate website, with recordings available for at least seven days post-conference.
BD (Becton, Dickinson and Company) reported Q4 2020 revenues of $4.784 billion, a 4.4% increase year-over-year. Despite strong contributions from COVID-19 diagnostics, diluted EPS fell to $0.36, down 20%. The BD Medical segment saw a 4.9% revenue decline, while the Life Sciences segment grew 31.2% due to strong diagnostic sales. The company expects fiscal 2021 revenue growth of high single to low double-digits and adjusted EPS between $12.40 and $12.60, reflecting growth over fiscal 2020.
BD (NYSE: BDX) announced key executive appointments effective January 1, 2021. Patrick Kaltenbach is named executive vice president and chief technology officer, succeeding John DeFord, who will retire. Kaltenbach, with nearly 30 years of R&D management experience, will drive BD's innovation strategy and oversee the 'Innovation and Growth Fund.' Additionally, Dave Hickey is promoted to executive vice president and president of the Life Sciences segment, succeeding Kaltenbach. Both leaders will report to CEO Tom Polen, focusing on enhancing BD's impact in medical technology.
CerTest Biotec and BD (Becton, Dickinson and Company) announced that their VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit for the BD MAX™ System has received CE marking under the IVD Directive (98/79/EC). This kit enables simultaneous testing for COVID-19, Influenza, and RSV, enhancing diagnostic capabilities during flu season. The BD MAX™ System is already used in numerous European laboratories, providing rapid results within two to three hours. BD's collaboration with CerTest aims to improve diagnostic efficiency and patient care during the winter season.
BD (Becton, Dickinson and Company) celebrates 25 years of partnership with Mercy Ships, announcing a donation of $1 million to support the launch of the Global Mercy, the world's largest NGO hospital ship. This contribution increases BD's total philanthropic investment in Mercy Ships to $2.5 million. The ship, set to sail to Africa in late 2021, features advanced medical facilities and aims to address the severe lack of surgical care, particularly in Africa, where 93% of the 18.6 million annual deaths due to inadequate surgical access occur.